Stories from the rare MC4R pathway disease community continue to inspire our work to transform the lives of patients and their families affected by hyperphagia and severe #obesity. Learn more about our focus on rare MC4R pathway diseases: https://rhythmtx.com/
About us
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway diseases. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information.
- Website
-
http://www.rhythmtx.com
External link for Rhythm Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- genetics, obesity, peptides, metabolism, rare disease, biotechnology, Pharmaceuticals, Research, Health, Medicine, Clinical Trials, Endocrinology, Orphan disease, Science, Advocacy, Epidemiology, Orphan drugs, Rare disease, and metabolic
Locations
-
Primary
222 Berkeley Street, 12th Floor
Boston, MA 02116, US
Employees at Rhythm Pharmaceuticals Inc.
Updates
-
We are excited to announce the appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer of Rhythm Pharmaceuticals! https://lnkd.in/e698tNAP
-
Rhythm was proud to be a Bronze sponsor of Foundation Fighting Blindness' global conference, VISIONS 2024! We enjoyed the opportunity to connect with members of the blind and low vision community and learn about the latest research advancements.
-
As we recognize #Juneteenth, we join with our colleagues in reaffirming our commitment to advancing equity and inclusion while honoring the diverse experiences that shape our communities. #Juneteenth2024
-
This spring, Rhythm delivered more than 30 presentations at 9 international conferences to share research on #hyperphagia and severe #obesity caused by rare neuroendocrine diseases with the scientific and medical communities. Learn more about our research: https://lnkd.in/egVsbhWv
-
We are excited for another day at #ASMBS2024 in San Diego! On Wednesday, June 12 from 6:45-7:45AM PST, Rhythm will host a symposium titled, "Not All Obesity is the Same - The Genetic Ripple Effect" led by Dr. Swain of Honor Health in Phoenix and Dr. Juliana Simonetti, Director of Obesity Medicine at the University of Utah's Comprehensive Weight Management Program. American Society For Metabolic And Bariatric Surgery (ASMBS)
-
Rhythm CEO David Meeker, M.D., will discuss our efforts to transform the care of patients with rare neuroendocrine diseases during a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 9:20-9:55 a.m. ET in Miami, FL.
-
We’re proud to show our support for the LGBTQ+ community as we honor #PRIDE2024! At Rhythm, we value the diverse perspectives of our team members and believe inclusivity is central to building an environment where everyone’s talents can shine. #PrideMonth